Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.

The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-

Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Phase 2
Completed
Conditions
First Posted Date
2003-08-29
Last Posted Date
2011-10-20
Lead Sponsor
City of Hope Medical Center
Registration Number
NCT00005857
Locations
🇺🇸

University of California Davis Cancer Center, Sacramento, California, United States

🇺🇸

St. Elizabeth's Medical Center of Boston, Brighton, Massachusetts, United States

🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

and more 1 locations

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Phase 3
Completed
Conditions
First Posted Date
2003-08-25
Last Posted Date
2023-06-15
Lead Sponsor
Eastern Cooperative Oncology Group
Registration Number
NCT00004125
Locations
🇺🇸

State University of New York - Upstate Medical University, Syracuse, New York, United States

🇺🇸

CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States

🇺🇸

CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States

and more 45 locations

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

First Posted Date
2003-08-07
Last Posted Date
2016-02-11
Lead Sponsor
Gynecologic Oncology Group
Target Recruit Count
13
Registration Number
NCT00066456
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

and more 4 locations

Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2003-08-07
Last Posted Date
2021-03-05
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
32
Registration Number
NCT00066677
Locations
🇺🇸

Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

First Posted Date
2003-08-07
Last Posted Date
2023-08-04
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
93
Registration Number
NCT00066443
Locations
🇨🇦

Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada

🇨🇦

Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

🇨🇦

CHA-Hopital Du St-Sacrement, Quebec City, Quebec, Canada

and more 2 locations

Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

First Posted Date
2003-07-18
Last Posted Date
2019-06-24
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
399
Registration Number
NCT00065182
Locations
🇵🇱

GSK Investigational Site, Szczecin Zdunowo 20, Poland

Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2003-07-09
Last Posted Date
2019-12-13
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
4
Registration Number
NCT00064012
Locations
🇺🇸

Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States

🇺🇸

Siteman Cancer Center, Saint Louis, Missouri, United States

🇺🇸

St. Louis University Hospital Cancer Center, Saint Louis, Missouri, United States

and more 18 locations

Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

Phase 2
Terminated
Conditions
First Posted Date
2003-06-27
Last Posted Date
2011-10-24
Lead Sponsor
Seagen Inc.
Registration Number
NCT00028483
Locations
🇺🇸

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

© Copyright 2024. All Rights Reserved by MedPath